Foundation Medicine, Inc. (NASDAQ:FMI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On June20, 2017, the Board of Directors of Foundation Medicine,
Inc. (the Company) received notice that David J. Daly intends to
resign as Chief Commercial Officer and General Manager, Clinical
Oncology Solutions of the Company due to personal reasons. The
resignation will be effective as of August11, 2017.
Item5.07 Submission of Matters to a Vote of Security
Holders.
At the Annual Meeting of Stockholders of Foundation Medicine,
Inc. (the Company) held on June20, 2017, all proposals brought
before the meeting and requiring approval were approved by the
requisite vote. The votes with respect to each proposal are set
forth below.
1. |
Proposal 1: Election of Directors |
|
|
|
|
|
|||
|
|
26,225,873 | 1,252,928 | 4,672,649 | |||
|
|
26,977,741 | 501,060 | 4,672,649 | |||
|
|
26,964,577 | 514,224 | 4,672,649 | |||
|
|
26,725,456 | 753,345 | 4,672,649 | |||
|
|
25,727,776 | 1,751,025 | 4,672,649 | |||
|
|
26,724,881 | 753,920 | 4,672,649 | |||
|
|
26,720,512 | 758,289 | 4,672,649 | |||
|
|
26,724,830 | 753,971 | 4,672,649 | |||
|
|
27,367,080 | 111,721 | 4,672,649 |
to the foregoing votes, the Director nominees listed above were
elected to serve on the Companys Board of Directors until the
Companys 2018 Annual Meeting of Stockholders.
2. |
Proposal 2: Ratification of KPMG LLP as the Companys Independent Registered Public Accounting Firm |
For: 33,491,795
Against: 6,904
Abstain: 8,007
to the foregoing votes, the appointment of KPMG LLP as the
Companys independent registered public accounting firm for the
year ending December31, 2017 was ratified and approved.
About Foundation Medicine, Inc. (NASDAQ:FMI)
Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer. Its other products include FoundationACT (Assay for Circulating Tumor deoxyribonucleic acid (DNA)), GeneKit, FoundationCORE, FoundationICE and the SmartTrials program.
